The role of melatonin in pathogenesis of cardiovascular diseases
https://doi.org/10.15829/1728-8800-2016-5-97-101
Abstract
The results presented, of laboratory and clinical studies of melatonine role in pathogenesis of cardiovascular diseases as arterial hypertension, coronary pathology. The influence of melatonin on atherogenesis is described, its impact on platelet aggregation. Increase of melatonin production in cardiovascular patients is probably the result of compensatory mechanisms activation at the stage of functional disorders with further exhaustion of compensatory mechanisms towards somatic disease development. As the severity of cardiovascular pathology increases, general production of melatonin declines, as well as its rhythmic of production turns disordered.
About the Authors
A. V. Budnevsky
N. N. Burdenko Voronezh State Medical University, Voronezh, Russia
Russian Federation
Russian Federation
E. S. Ovsyannikov
N. N. Burdenko Voronezh State Medical University, Voronezh, Russia
Russian Federation
Russian Federation
N. V. Filina
N. N. Burdenko Voronezh State Medical University, Voronezh, Russia
Russian Federation
Russian Federation
References
1. Tosches MA. Melatonin Signaling Controls Circadian Swimming Behavior in Marine Zooplankton. 2014; 159(1): 46-57.
2. Komarov FI, Rapoport SI, Malinovskaya NK, et al. Melatonin is normal and pathology. Moscow: 2006; 308 (Комаров Ф.И., Рапопорт С.И., Малиновская Н.К. и др. Мелатонин в норме и патологии. М.: 2004;308).
3. Breus TK, Rapoport SI. Magnetic storms: medicobiological and geophysical aspects. Sovetskyi sport, 2011; 192 (Бреус Т.К., Рапопорт С.И. Магнитные бури: медико-биологические и геофизические аспекты. Советский спорт, 2011; 192).
4. Girotti L, Lago M, Ianovsky O, Carbajales J et al. Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease. J. Pineal Res. 2010; 29:138–42.
5. Weydah A, Sothern RB, Cornelissen G et al. Geomagnetic activity influences the melatonin secretion at latitude 70 degrees N. Biomed. Pharmacother. 2006; 55(1):57–62.
6. Chazova IE, Ratova LG, Boytsov SA, et al. Diagnostics and treatment of arterial hypertension. Recommendations of the Russian medical society about an arterial hypertension and All-Russian science foundation of cardiologists. Sistemnye gipertenzii. 2010; 3:5-26 (Чазова И.Е., Ратова Л.Г., Бойцов С.А. и др. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Системные гипертензии. 2010; 3:5–26) .
7. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2006; 46(1): 156–61.
8. Komarov FI, Rapoport SI, Malinovskaya NK. Daily rhythms in clinic of internal diseases. Klinicheskaya meditsina. 2005; 8: 8-12 (Комаров Ф.И., Рапопорт С.И., Малиновская Н.К. Суточные ритмы в клинике внутренних болезней. Клиническая медицина. 2005; 8: 8–12).
9. Kovalzon VM. Somnology bases: physiology and neurochemistry of the cycle "dream -wakefulness". M.: BINOM. Laboratoriya znaniy. 2011. (Ковальзон В.М. Основы сомнологии: физиология и нейрохимия цикла «сон-бодрствование». М.: БИНОМ. Лаборатория знаний. 2011).
10. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence based treatment of insomnia, parasomnias and circadian rhythm disorders. J. Psychopharmacol. 2010; 24(11): 1577–1601.
11. Huang L, Zhang C, Hou Y, et al. Blood pressure reducing effects of piromelatine and melatonin in spontaneously hypertensive rats. Eur. Rev. Med. Pharmacol. Sci. 2013; 17(18): 2449–56.
12. Jonas M, Garfinkel D, Zisapel N, et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press. 2006; 12(1):19–24.
13. Birau N, Peterssen U, Meyer C, et al. Hypotensive effect of melatonin in essential hypertension. IRSC Med. Sci.2006; 9: 906.
14. Cagnacci A, Arangino S, Angiolucci M, et al. Potentially beneficial cardiovascular effects of melatonin administration in women. J. Pineal Res. 2007; 22:16–9.
15. Cagnacci A, Arangino S, Angiolucci M, et al. Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy. Clin. Endocrinol. 2006; 54: 261–6.
16. Girouard H, Chulak C, Lejossec M, et al. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. J. Hypertens. 2006; 19(8):1369–77.
17. Martynov AI, Vane AM, Ostroumova OD, et al. Application of a zopiklon for correction of the increased arterial pressure in a cycle a dream-wakefulness in elderly patients with essential arterial hypertension and an insomniya. Kardiologiya. 2007; 8: 11-4 (Мартынов А.И., Вейн А.М., Остроумова О.Д. и др. Применение зопиклона для коррекции повышенного артериального давления в цикле сон-бодрствование у пожилых больных с эссенциальной артериальной гипертензией и инсомнией. Кардиология. 2007; 8: 11–14).
18. Grossman E, Laudon M, Yalcin R, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am. J. Med. 2006; 119(10): 898–902.
19. Cagnacci A, Cannoletta M, Renzi A, et al. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am. J. Hypertens. 2006; 12(18): 1614–18.
20. Rechcinski T, Trzos E, Wierzbowska-Drabik K, et al. Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability. Hypertens. Res. 2010; 33(1):56–61.
21. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc. Health Risk Manag. 2011; 7:577–84.
22. Rapoport SI, Shatalova AM, Malinovsky NK. Produсtion of melatonin in patients with an idiopathic hypertensia. Klinicheskaya meditsina. 2006; 6: 21-4 (Рапопорт С.И., Шаталова А.М., Малиновская Н.К. Продукция мелатонина у больных гипертонической болезнью. Клиническая медицина. 2006; 6: 21–4).
23. Zamotaev YuN. Use of melatonin for correction of sleep disorders in persons with arterial hypertension occupied with shift work on conveyor production. Klinicheskaya meditsina. 2012; 3: 44-6 (Замотаев Ю.Н. Применение мелатонина для коррекции нарушений сна у лиц с артериальной гипертензией, занятых сменной работой на конвейерном производстве. Клиническая медицина. 2012; 3: 44–6).
24. Nava M, Quiroz Y, Vaziri N, et al. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am. J. Physiol. Renal. Physiol. 2006; 284: 447–54.
25. Zaslavskaya RM, Logvinenko SI, Shcherban EA. Melatonin in complex treatment of patients with stable angina and arterial hypertension. Klinicheskaya meditsina 2008; 9: 64-7 (Заславская Р.М., Логвиненко С.И., Щербань Э.А. Мелатонин в комплексном лечении больных стабильной стенокардией и артериальной гипертонией. Клиническая медицина. 2008; 9: 64–7).
26. Kawashima K, Nagakura A, Wurzburger RJ, et al. Melatonin in serum and the pineal of spontaneously hypertensive rats. Clin. Exp. Hypertens. A.2006; 6: 1517–28.
27. Maurizi CP. Short note: The fetal origins hypothesis: linking pineal gland hypoplasia with coronary heart disease and stroke.Med. Hypotheses. 2008; 50: 357–8.
28. Cuzzocrea S, Reiter RJ. Pharmacological action of melatonin in shock, inflammation and ischemia reperfusion injury. Eur. J. Pharmacol. 2010; 426:1–10.
29. Sewerynek E. Melatonin and the cardiovascular system. Neuroendocrinol. Lett. 2006; 23(1):79–83.
30. Altun A, Yaprak M, Aktoz M, et al. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci. Lett. 2006; 327:143–5.
31. Girotti L, Lago M, Ianovsky O, et al. Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease. J. Pineal Res. 2010; 29:138–42.
32. Lee YM, Chen HR, Hsiao G, et al. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. J. Pineal Res. 2002; 33:72–80.
33. Pei Z, Pang SF, Cheung RT. Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J. Pineal Res. 2012; 32: 168–72.
34. Sahna E, Olmez E, Acet A. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: can the incidence of sudden cardiac death be reduced. J. Pineal Res. 2006; 32:194–8.
35. Del Zar MM, Martinuzzo M, Falcon C, et al. Inhibition of human platelet aggregation and thromboxane B2 production by melatonin. Evidence for a diurnal variation. J. Clin. Endocrinol. Metab. 2010; 70: 246–51.
36. Martin FJ, Atienza G, Aldegunde M, et al. Melatonin effect on serotonin uptake and release in rat platelets: diurnal variation in responsiveness. Life Sci. 2006; 53: 1079–87.
Supplementary files
|
|
1. Направление | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(114KB)
|
Indexing metadata ▾ | |
|
2. титульный лист | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(12KB)
|
Indexing metadata ▾ | |
Review
For citations:
Budnevsky A.V., Ovsyannikov E.S., Filina N.V. The role of melatonin in pathogenesis of cardiovascular diseases. Cardiovascular Therapy and Prevention. 2016;15(5):97-101. (In Russ.) https://doi.org/10.15829/1728-8800-2016-5-97-101
Views:
1168
Email this article 
